1α,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice

Journal of Investigative Dermatology

Volumn 113, Issue 6, 1999, Pages 1082-1089

  Dam, Tomas Norman ^a,c   Kang, Sewon ^a   Nickoloff, Brian J ^b   Voorhees, J J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Immune deviation; Interleukin 10; Superantigens; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; STAPHYLOCOCCUS ENTEROTOXIN B; CALCITRIOL; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACANTHOSIS; ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LEUKOCYTE COUNT; MALE; MOUSE; NONHUMAN; PARAKERATOSIS; PRIORITY JOURNAL; PSORIASIS; SCID MOUSE; SKIN GRAFT; T LYMPHOCYTE; XENOGRAFT; ANIMAL; CD4 CD8 RATIO; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; MOUSE MUTANT; SKIN TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CALCITRIOL; CD4-CD8 RATIO; CYCLOSPORINE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; MICE; MICE, SCID; PSORIASIS; RECEPTORS, INTERLEUKIN-2; SKIN TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033233456     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1999.00811.x     Document Type: Article

References (50)

1. Asadullah K, Sterry W, Stephanek K, et al: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 101:783-794, 1998
2. Asadullah K, Docke WD, Ebeling M, et al: Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 135:187-192, 1999
3. Baker BS, Swain AF, Fry L, Valdimarsson H: Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 110:555-564, 1984
4. Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC: Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 67:607-613, 1988
5. Boehncke WH, Zollner TM, Dressel D, Kaufmann R: Induction of psoriasiform inflammation by a bacterial superantigen in the SCID-hu xenogeneic transplantation model. J Cutan Pathol 24:1-7, 1997
6. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH: Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 275:181-189, 1983
7. Cook PW, Piepkorn M, Clegg CH, Plowman GD, DeMay JM, Brown JR, Pittelkow MR: Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J Clin Invest 100:2286-2294, 1997
8. Cooper KD, Baadsgaard O, Duell E, Fisher G, Ellis CN, Voorhees JJ: Langerhans cell sensitivity to in vitro versus in vivo loading with cyclosporine A [letter; comment]. J Invest Dermatol 98:259-261, 1992
9. 3 Analog Calcipotriol Suppresses the Number and Antigen-Presenting Function of Langerhans Cells in Normal Human Skin. J Invest Dermatol 1:S72-S76, 1996
10. de Jong EM, van de Kerkhof PC: Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: modulations and interrelations [see comments]. Br J Dermatol 124:221-229, 1991
11. Del Prete G, Maggi E, Romagnani S: Human Th1 and Th2 cells: functional properties, mechanisms of regulation, and role in disease. Lab Invest 70:299-306, 1994
12. Ellis CN, Fradin MS, Messana JM, et al: Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial [see comments]. N Engl J Med 324:277-284, 1991
13. Gilhar A, David M, Ullmann Y, Berkutski T, Kalish RS: T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol 109:283-288, 1997
14. Kang S, Yi S, Griffiths CE, Fancher L, Hamilton TA, Choi JH: Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 138:77-83, 1998
15. Kragballe K, Beck HI, Sogaard H: Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind study. Br J Dermatol 119:223-230, 1988
16. Kragballe K, Gjertsen BT, De Hoop D, et al: Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris [published erratum appears in Lancet 1991 April 20; 337 (8747): 988] [see comments]. Lancet 337:193-196, 1991
17. Kragballe K, Dam TN, Hansen ER, Baadsgaard O, Gronhoj Larsen F, Sondergaard J, Axelsen MB: Efficacy and safety of the 20-epi-vitamin D3 analogue KH 1060 in the topical therapy of psoriasis: results of a dose-ranging study. Acta Derm Venereol (Stockh) 74:398-402, 1994
18. Kurimoto I, Arana M, Streilein JW: Role of dermal cells from normal and ultraviolet B-damaged skin in induction of contact hypersensitivity and tolerance. J Immunol 152:3317-3323, 1994
19. Lemire JM: Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 53:599-602, 1995
20. Lemire JM, Adams JS, Kermani-Arab V, Bakke AC, Sakai R, Jordan SC: 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 134:3032-3035, 1985
21. Leung DY, Travers JB, Norris DA: The role of superantigens in skin disease. J Invest Dermatol 105:37S-42S, 1995
22. Lu I, Gilleaudeau P, McLane JA, et al: Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infiltration in psoriatic plaques by topical calcitriol. J Cutan Pathol 23:419-430, 1996
23. Meehan MA, Kerman RH, Lemire JM: 1,25-Dihydroxyvitamin D3 enhances the generation of nonspecific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR. Cell Immunol 140:400-409, 1992
24. Morimoto S, Kumahara Y: A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Cell 57:555-556, 1985
25. Morimoto S, Yoshikawa K, Kozuka T, et al: An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol 115:421-429, 1986
26. Mortensen JT, Brinck P, Binderup L: Toxicity of vitamin D analogues in rats fed diets with standard or low calcium contents. Pharmacol Toxicol 72:124-127, 1993
27. Mozzanica N, Pigatto PD, Finzi AF: Cyclosporin in psoriasis: pathophysiology and experimental data. Dermatology 187 (Suppl. 1):3-7, 1993
28. Mozzanica N, Cattaneo A, Schmitt E, Diotti R, Finzi AF: Topical calcipotriol for psoriasis - an immunohistologic study. Acta Derm Venereol (Suppl.)(Stockh) 186:171-172, 1994
29. Müller K, Bendtzen K: Inhibition of human T lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D3. Differential effects on CD45RA+ and CD45R0+ cells. Autoimmunity 14:37-43, 1992
30. Müller K, Svenson M, Bendtzen K: 1 alpha,25-Dihydroxyvitamin D3 and a novel vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 in vitro. Immunol Lett 17:361-365, 1988
31. Nickoloff BJ: The cytokine network in psoriasis. Arch Dermatol 127:871-884, 1991
32. Nickoloff BJ: Animal models of psoriasis. Exp Opin Invest Drugs 8(4):393-401, 1999
33. Nickoloff BJ, Wrone-Smith T: Animal models of psoriasis [letter]. Nat Med 3:475-476, 1997
34. Nickoloff BJ, Wrone-Smith T: Superantigens, autoantigens, and pathogenic T cells in psoriasis [letter]. J Invest Dermatol 110:459-460, 1998
35. Nickoloff BJ, Fivenson DP, Kunkel SL, Strieter RM, Turka LA: Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sézary syndrome, but not in psoriatic plaques. Clin Immunol Immunopathol 73:63-68, 1994
36. Nickoloff BJ, Kunkel SL, Burdick M, Strieter RM: Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 146:580-588, 1995
37. Olaniran AK, Baker BS, Paige DG, Garioch JJ, Powles AV, Fry L: Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res 288:421-425, 1996
38. Reich K, Bruck M, Grafe A, Vente C, Neumann C, Garbe C: Treatment of psoriasis with interleukin-10 [letter]. J Invest Dermatol 111:1235-1236, 1998
39. Rigby WF, Hamilton BJ, Waugh MG: 1,25-Dihydroxyvitamin D3 modulates the effects of interleukin 2 independent of IL-2 receptor binding. Cell Immunol 125:396-414, 1990a
40. Rigby WF, Waugh M, Graziano RF: Regulation of human monocyte HLA-DR and CD4 antigen expression, and antigen presentation by 1,25-dihydroxyvitamin D3, Blood 76:189-197, 1990b
41. Schlaak JF, Buslau M, Jochum W, et al: T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 102:145-149, 1994
42. Schon MP, Detmar M, Parker CM: Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat Med 3:183-188, 1997
43. Sigmundsdóttir H, Sigurgeirsson B, Troye-Blomberg M, Good MF, Valdimarsson H, Jonsdóttir I: Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand J Immunol 45:688-697, 1997
44. Stumpf WE, Sar M, Reid FA, Tanaka Y, Deluca HF: Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 206:1188-1190, 1979
45. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol 101:701-705, 1993
46. Valdimarsson H, Baker BS, Jonsdóttir I, Powles A, Fry L: Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 16:145-149, 1995
47. Valdimarsson H, Sigmundsdóttir H, Jonsdóttir I: Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin? Clin Exp Immunol 107 (Suppl. 1):21-24, 1997
48. van de Kerkhof PC: Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol 132:675-682, 1995
49. Volpert OV: Inhibition of angiogenesis by interleukin 4. J Exp Med 188:1039-1046, 1998
50. Wrone-Smith T, Nickoloff BJ: Dermal injection of immunocytes induces psoriasis [see comments]. J Clin Invest 98:1878-1887, 1996